Next Science Limited (NXS-ASX)NXS is commercialising its Xbio technology platform to disrupt biofilm structures that are integral to myriad bacterial infections. Several product approvals and distribution agreements are in place in the US market, with several more to come in CY20, in addition to pending approvals for the European market. NXS has a unique position in addressing antibiotic resistance, with several products having blockbuster potential. We believe CY20 is an important year in the commercial development of NXS which should drive investor sentiment.
https://www.livewiremarkets.com/wires/16-top-australian-stock-picks
- Forums
- ASX - By Stock
- NXS
- NXS in Canncord Genuity's top 16 picks
NXS in Canncord Genuity's top 16 picks
Featured News
Add NXS (ASX) to my watchlist
|
|||||
Last
28.0¢ |
Change
-0.020(6.67%) |
Mkt cap ! $81.67M |
Open | High | Low | Value | Volume |
30.0¢ | 30.0¢ | 28.0¢ | $20.18K | 70.31K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 26369 | 27.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
29.0¢ | 10384 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 26369 | 0.275 |
1 | 30000 | 0.270 |
1 | 25000 | 0.260 |
1 | 19549 | 0.255 |
1 | 2500 | 0.245 |
Price($) | Vol. | No. |
---|---|---|
0.290 | 11920 | 2 |
0.295 | 5890 | 2 |
0.300 | 32437 | 1 |
0.305 | 37749 | 2 |
0.310 | 15000 | 1 |
Last trade - 10.40am 25/07/2024 (20 minute delay) ? |
Featured News
NXS (ASX) Chart |
The Watchlist
LGP
LITTLE GREEN PHARMA LTD
Paul Long, CEO
Paul Long
CEO
Previous Video
Next Video
SPONSORED BY The Market Online